Changes in function of HIV-specific T-cell responses with increasing time from infection

Viral Immunology

Volumn 23, Issue 2, 2010, Pages 159-168

  Ndongala, Michel L ^a   Kamya, Philomena ^a   Boulet, Salix ^a   Peretz, Yoav ^b   Rouleau, Danielle ^b   Tremblay, Cécile ^b   Leblanc, Roger ^a   Côté, Pierre ^c   Baril, Jean Guy ^c   Thomas, Réjean ^d   Vézina, Sylvie ^d   Boulassel, Mohamed R ^e   Routy, Jean Pierre ^a   Sékaly, Rafick P ^b   Bernard, Nicole F ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Clinique Medicale du Quartier Latin   (Canada)

^d Clinique Medicale l'Actuel   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; T LYMPHOCYTE;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; PEPTIDES; PROTEOME; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TIME FACTORS;

EID: 77953939935     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0084     Document Type: Article

References (68)

1. Addo MM, Yu XG, Rathod A, et al.: Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77: 2081-2092.
2. Allen TM, Altfeld M, Geer SC, et al.: Selective escape from CD8+T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005;79:13239-13249.
3. Allen TM, Altfeld M, Yu XG, et al.: Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004;78:7069-7078.
4. Almeida JR, Price DA, Papagno L, et al.: Superior control of HIV-1 replication by CD8+T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007;204:2473-2485.
5. Alter G, Hatzakis G, Tsoukas CM, et al.: Longitudinal assessment of changes in HIV-specific effector activity in HIVinfected patients starting highly active antiretroviral therapy in primary infection. J Immunol 2003;171:477-488.
6. Alter G, Merchant A, Tsoukas CM, Rouleau D, et al.: Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis 2002;185:755-765.
7. Altfeld M, Rosenberg ES, Shankarappa R, et al.: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;193: 169-180.
8. Betts MR, Ambrozak DR, Douek DC, et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
9. Betts MR, Nason MC, West SM, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+T cells. Blood 2006;107:4781-4789.
10. Bhattacharya T, Daniels M, Heckerman D, et al.: Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007;315:1583-1586.
11. Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB: Virus-specific CD8+cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
12. Boulassel MR, Spurll G, Rouleau D, et al.: Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. J Clin Apher 2003;18: 55-60.
13. Boulet S, Ndongala ML, Peretz Y, et al.: A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses. J Immunol Methods 2007;320:18-29.
14. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200:749-759.
15. Brumme ZL, Tao I, Szeto S, et al.: Human leukocyte antigenspecific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS 2008; 22:1277-1286.
16. Carrington M, and O'Brien SJ: The influence of HLA genotype on AIDS. Annu Rev Med 2003;54:535-551.
17. Champagne P, Ogg GS, King AS, et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410:106-111.
18. Clark SJ, Saag MS, Decker WD, et al.: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-960.
19. Daar ES, Moudgil T, Meyer RD, and Ho DD: Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324: 961-964.
20. Dalod M, Dupuis M, Deschemin JC, et al.: Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest 1999;104:1431-1439.
21. Dalod M, Fiorentino S, Delamare C, Rouzioux C, Sicard D, Guillet JG, and Gomard E: Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+cell counts: correlations with various parameters of disease progression. AIDS Res Hum Retroviruses 1996;12:497-506.
22. Darrah PA, Patel DT, De Luca PM, et al.: Multifunctional Th1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-850.
23. Douek DC, Brenchley JM, Betts MR, et al.: HIV preferentially infects HIV-specific CD4+T cells. Nature 2002;417:95-98.
24. Draenert R, Altfeld M, Brander C, et al.: Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 2003;275:19-29.
25. Emu B, Sinclair E, Favre D, et al.: Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005;79: 14169-14178.
26. Feeney ME, Tang Y, Roosevelt KA, et al.: Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004;78:8927-8930.
27. Goepfert PA, Lumm W, Farmer P, et al.: Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008;205: 1009-1017.
28. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, and Pantaleo G: Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006;211:236-254.
29. Harari A, Petitpierre S, Vallelian F, and Pantaleo G: Skewed representation of functionally distinct populations of virusspecific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-972.
30. Harari A, Vallelian F, Meylan PR, and Pantaleo G: Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005;174:1037-1045.
31. Kaslow RA, Carrington M, Apple R, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-411.
32. Kelleher AD, Long C, Holmes EC, et al.: Clustered mutations in HIV-1 gag are consistently required for escape from HLAB27- restricted cytotoxic T lymphocyte responses. J Exp Med 2001;193:375-386.
33. Kiepiela P, Leslie AJ, Honeyborne I, et al.: Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004;432:769-775.
34. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
35. Leslie A, Price DA, Mkhize P, et al.: Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 2006;177:4699-4708.
36. Leslie AJ, Pfafferott KJ, Chetty P, et al.: HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004;10:282-289.
37. Lichterfeld M, Kaufmann DE, Yu XG, et al.: Loss of HIV-1- specific CD8+T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004;200:701-712.
38. Lichterfeld M, Yu XG, Mui SK, et al.: Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)- specific CD8+T cells after early HIV-1 infection. J Virol 2007;81:4199-4214.
39. Martro E, Suligoi B, Gonzalez V, Bossi V, Esteve A, Mei J, and Ausina V: Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections. J Clin Microbiol 2005;43:6197-6199.
40. Matano T, Shibata R, Siemon C, Connors M, Lane HC, and Martin MA: Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian= human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998;72:164-169.
41. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT Jr, and Connors M: High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA 2001;98:13878-13883.
42. Mehandru S, Poles MA, Tenner-Racz K, et al.: Primary HIV-1 infection is associated with preferential depletion of CD4+T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
43. Migueles SA, Laborico AC, Shupert WL, et al.: HIV-specific CD8+T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
44. Migueles SA, Sabbaghian MS, Shupert WL, et al.: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000;97:2709-2714.
45. Miura T, Brockman MA, Brumme ZL, et al.: HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2009;83:140-149.
46. Miura T, Brockman MA, Schneidewind A, et al.: HLAB57= B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye recognition. J Virol 2009;83:2743-2755.
47. Miura T, Brumme CJ, Brockman MA, et al.: HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 2009;83:3407-3412.
48. Mueller SN, and Ahmed R: High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2009;106:8623-8628.
49. Ndongala ML, Peretz Y, Boulet S, et al.: HIV Gag p24 specific responses secreting IFN-gamma and=or IL-2 in treatmentnaive individuals in acute infection early disease (AIED) are associated with low viral load. Clin Immunol 2009;131:277-287.
50. Peretz Y, Alter G, Boisvert MP, Hatzakis G, Tsoukas CM, and Bernard NF: Human immunodeficiency virus (HIV)- specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J Virol 2005;79:4908-4917.
51. Peretz Y, Ndongala ML, Boulet S, et al.: Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin Immunol 2007;124:57-68.
52. Phillips AN: Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996;271:497-499.
53. Pulendran B, and Ahmed R: Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006;124:849-863.
54. Querec T, Bennouna S, Alkan S, et al.: Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006;203:413-424.
55. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia. Science 1997;278:1447-1450.
56. Rousseau CM, Daniels MG, Carlson JM, et al.: HLA class Idriven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 2008;82:6434-6446.
57. Schmitz JE, Kuroda MJ, Santra S, et al.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-860.
58. Seder RA, Darrah PA, and Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-258.
59. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, and Lieberman J: Impaired function of circulating HIVspecific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 2000;96:3094-3101.
60. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity. Nature 2002;415:331-335.
61. Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T, Carcelain G, and Autran B: A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003;272:23-34.
62. Trachtenberg E, Korber B, Sollars C, et al.: Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9:928-935.
63. Wherry EJ, Blattman JN, Murali-Krishna K, van der MR, and Ahmed R: Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003;77:4911-4927.
64. Wilson JD, Imami N, Watkins A, et al.: Loss of CD4+T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000;182:792-798.
65. Wilson JD, Ogg GS, Allen RL, et al.: Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 2000;14:225-233.
66. Younes SA, Trautmann L, Yassine-Diab B, et al.: The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+T cells. J Immunol 2007;178:788-797.
67. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, and Sekaly RP: HIV-1 viremia prevents the establishment of interleukin 2-producing HIVspecific memory CD4+T cells endowed with proliferative capacity. J Exp Med 2003;198:1909-1922.
68. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, and Pantaleo G: HIV-1-specific IFN-gamma=IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1- specific CD8 T cells. Proc Natl Acad Sci USA 2005;102: 7239-7244.